Drug intelligence / Profile preview

BG22

Development stage: Preclinical
Lead developer: BioSTAR Group
Modality: Small Molecules, Peptides

Overview

BG22 is a chemical drug candidate developed by Beijing Biostar Pharmaceuticals. It is in preclinical development for the treatment of neoplasms, specifically solid tumors. While detailed mechanistic information is not publicly available, literature suggests that BG22 may be related to BPI-derived peptide endotoxin antagonists, which are designed to neutralize endotoxins and inhibit tumor necrosis factor-alpha secretion. This class of compounds has been investigated for their potential to modulate immune responses and reduce inflammation associated with tumor progression[1].

Targets

Neuraminidase

Beyond the preview

Go deeper on BG22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG22.

Explore the full profile